期刊文献+

舒利迭治疗稳定期慢性阻塞性肺疾病53例临床分析 被引量:1

Shurly repeat treatment stabilization period chronicity blocking lung disease 53 example clinical analysis
原文传递
导出
摘要 目的:讨论使用舒利迭治疗稳定期慢性阻塞性肺疾病即COPD的疗效。方法:收集我院确诊为慢性阻塞性疾病的IV期患者53例,将慢性阻塞性疾病的患者随进分为观察组和对照组。观察组除了进行心理健康辅导和化痰平喘等治疗外还给予舒利迭(50ug/500ug),每日2次,每次1吸,持续给药7个月;对照组不使用舒利迭药物。分别对两组患者的肺功能指标、治疗状况、6分钟步行距离(6-MWD)、加重为急性肺疾病次数和治疗后期的第一次急性加重的时间等观察指标进行比较,判断药物的治疗效果。结果:在试验前对对照组和观察组进行呼吸问卷调查,FEV/FVC和FEV的最大预计值的无显著性差异(P〉0.05),对照组和观察组观察指标有显著性差异(P〈0.05)。长期使用舒利迭治疗慢性阻塞性肺疾病可增加6-MWD和FEV。试验期间的急性加重肺疾病次数对照组为49次,观察组为27次。治疗后期的第一次急性加重观察组的时间明显比对照组要长。结论:长期使用舒利迭治疗稳定期的慢性阻塞性肺疾病能改善患者的症状,提高肺功能,提高患者的生病质量。 Objective: The discussion uses the Shurly repeat to treat the stabilization period chronicity blocking lung disease is the COPD curative effect. Methods:Collects my courtyard diagnosis for the chronic blocking disease IV issue of patient 53 examples, along with enters the chronic blocking disease patient divides into the observation group and the control group. The observation group except carries on psychologically healthy counselling and the phlegm reduction breathes heavily and so on outside the treatments also to give Shurly evenly the repeat (50ug/500ug),daily 2 times,each time 1 attracts,continues to give the medicine for 7 months;The control group does not use the Shurly repeat medicine. Separately to two group of patient's lung function targets, the treatment condition,6 minutes walks is away from (6-MWD) ,the aggravation for the acute lung disease number of times and treatment later period first acute aggravation observation targets and so on time carries on the comparison,the judgment medicine treatment result. Results:Carries on the breath questionnaire survey before the experiment to the control group and the observation group,FEV/FVC and the FEV biggest predicted value non--significance difference (P〉0.05), the control group and the observation group observe the target to have the significance difference (P〈0.05). For a long time uses the Shurly repeat treatment chronicity blocking lung disease to be possible to increase 6-MWD and FEV. The experimental period acute aggravation lung disease number of times control group is 49 times, the observation group is 27 times. The treatment later period first acute aggravation'observation group's time wants obviously compared to the control group long. Conelusion: Uses the Shurly repeat treatment stabilization period the chronic blocking lung disease to be able for a long time to improve patient's symptom, enhances the lung function, enhances the patient to fall ill the quality.
作者 陈玺 魏春林
出处 《按摩与康复医学》 2011年第8期130-131,共2页 Chinese Manipulation and Rehabilitation Medicine
关键词 慢性阻塞性肺疾病 舒利迭 Chronic blocking lung disease Shurly repeat
  • 相关文献

参考文献2

二级参考文献11

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 2GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989. 被引量:1
  • 3Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946. 被引量:1
  • 4Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012. 被引量:1
  • 5冉丕鑫 王辰 姚婉贞 等.我国部分地区慢性阻塞性肺疾病流行病学研究[J].中华结核和呼吸杂志,2007,. 被引量:2
  • 6Pauwels RA,Buist AS,Calverley PM,et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease ( GOLD ) Workshop summary[].American Journal of Respiratory and Critical Care Medicine.2001 被引量:1
  • 7Burge PS,Calverley PM,Jones PW,et al.Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial[].British Medical Journal.2000 被引量:1
  • 8Lung Health Study Research Group.Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease[].The New England Journal of Medicine.2000 被引量:1
  • 9Paggiaro PL,Dahle R,Bakran I,et al.Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease.International COPD Study Group[].The Lancet.1998 被引量:1
  • 10王辰,杜敏捷,曹大德,翁心植,吴小青,常青,王瑜.慢性肺原性心脏病急性发作期肺细小动脉血栓形成的病理观察[J].中华医学杂志,1997,77(2):123-125. 被引量:498

共引文献8236

同被引文献13

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部